1: Ortiz D, Forquer I, Boitz J, Soysa R, Elya C, Fulwiler A, Nilsen A, Polley T, Riscoe MK, Ullman B, Landfear SM. Targeting the Cytochrome bc1 Complex of Leishmania Parasites for Discovery of Novel Drugs. Antimicrob Agents Chemother. 2016 Jun 13. pii: AAC.00850-16. [Epub ahead of print] PubMed PMID: 27297476.
2: Lawres LA, Garg A, Kumar V, Bruzual I, Forquer IP, Renard I, Virji AZ, Boulard P, Rodriguez EX, Allen AJ, Pou S, Wegmann KW, Winter RW, Nilsen A, Mao J, Preston DA, Belperron AA, Bockenstedt LK, Hinrichs DJ, Riscoe MK, Doggett JS, Ben Mamoun C. Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone. J Exp Med. 2016 Jun 27;213(7):1307-18. doi: 10.1084/jem.20151519. Epub 2016 Jun 6. PubMed PMID: 27270894; PubMed Central PMCID: PMC4925016.
3: Stickles AM, Smilkstein MJ, Morrisey JM, Li Y, Forquer IP, Kelly JX, Pou S, Winter RW, Nilsen A, Vaidya AB, Riscoe MK. Atovaquone and ELQ-300 combination therapy: A novel dual-site cytochrome bc1 inhibition strategy for malaria. Antimicrob Agents Chemother. 2016 Jun 6. pii: AAC.00791-16. [Epub ahead of print] PubMed PMID: 27270285.
4: Stickles AM, de Almeida MJ, Morrisey JM, Sheridan KA, Forquer IP, Nilsen A, Winter RW, Burrows JN, Fidock DA, Vaidya AB, Riscoe MK. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. Antimicrob Agents Chemother. 2015 Apr;59(4):1977-82. doi: 10.1128/AAC.04149-14. Epub 2015 Jan 20. PubMed PMID: 25605352; PubMed Central PMCID: PMC4356778.
5: Nilsen A, Miley GP, Forquer IP, Mather MW, Katneni K, Li Y, Pou S, Pershing AM, Stickles AM, Ryan E, Kelly JX, Doggett JS, White KL, Hinrichs DJ, Winter RW, Charman SA, Zakharov LN, Bathurst I, Burrows JN, Vaidya AB, Riscoe MK. Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers. J Med Chem. 2014 May 8;57(9):3818-34. doi: 10.1021/jm500147k. Epub 2014 Apr 18. PubMed PMID: 24720377; PubMed Central PMCID: PMC4018401.
6: Ojha PK, Roy K. Exploration of important sites of antimalarial Endochins for optimum structural modification using group-based QSAR (G-QSAR) modeling. Curr Comput Aided Drug Des. 2013 Sep;9(3):336-49. PubMed PMID: 24010932.
7: Li J, Li S, Bai C, Liu H, Gramatica P. Structural requirements of 3-carboxyl-4(1H)-quinolones as potential antimalarials from 2D and 3D QSAR analysis. J Mol Graph Model. 2013 Jul;44:266-77. doi: 10.1016/j.jmgm.2013.07.004. Epub 2013 Jul 19. PubMed PMID: 23911994.
8: Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, Bordón C, Charman SA, Katneni K, Schultz T, Burrows JN, Hinrichs DJ, Meunier B, Carruthers VB, Riscoe MK. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15936-41. Epub 2012 Sep 10. PubMed PMID: 23019377; PubMed Central PMCID: PMC3465437.
9: Winter R, Kelly JX, Smilkstein MJ, Hinrichs D, Koop DR, Riscoe MK. Optimization of endochin-like quinolones for antimalarial activity. Exp Parasitol. 2011 Feb;127(2):545-51. doi: 10.1016/j.exppara.2010.10.016. Epub 2010 Oct 30. PubMed PMID: 21040724; PubMed Central PMCID: PMC3025093.
10: Cross RM, Monastyrskyi A, Mutka TS, Burrows JN, Kyle DE, Manetsch R. Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity. J Med Chem. 2010 Oct 14;53(19):7076-94. doi: 10.1021/jm1007903. PubMed PMID: 20828199.
11: Winter RW, Kelly JX, Smilkstein MJ, Dodean R, Hinrichs D, Riscoe MK. Antimalarial quinolones: synthesis, potency, and mechanistic studies. Exp Parasitol. 2008 Apr;118(4):487-97. Epub 2007 Nov 7. PubMed PMID: 18082162; PubMed Central PMCID: PMC2323441.
12: GINGRICH WD, DARROW EM. The effect of endochin on experimental toxoplasmosis. Am J Trop Med Hyg. 1951 Jan;31(1):12-7. PubMed PMID: 14799708.